Results 21 to 30 of about 11,904 (210)

FDA Approval of Donanemab-azbt: A New Dawn in Alzheimer's Disease Treatment. [PDF]

Health Sci Rep
ABSTRACT Background Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine are commonly used to enhance cognitive function by ...
Riaz R, Fatima M, Ramzan S, Rathi D, Fatima F, Farooq M, Shaukat A, Khaliq N, Akilimali A.   +8 more
europepmc   +2 more sources

Structure of rivastigmine.

, 2023
BackgroundRivastigmine is a pseudo-irreversible cholinesterase inhibitor used for therapy of Alzheimer’s disease and non-Alzheimer dementia syndromes. In humans, rivastigmine can cause significant gastrointestinal side effects that can limit its clinical
Darina Kohoutova (788793), Martin Valis (9936308), Ondrej Soukup (1475038), Stanislav Rejchrt (8318142), Jana Zdarova Karasova (6898799), Veronika Knoblochova (16007227), Ilja Tacheci (8357547), Vera Radochova (8357544), Jan Bures (8318145), Chrysostomi Christina Tsianou (16007224), Jaroslav Kvetina (8357541)   +10 more
core   +1 more source

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. [PDF]

PLoS ONE, 2017
To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial ...
Jose A Muñoz-Moreno, Anna Prats, José Moltó, Maite Garolera, Núria Pérez-Álvarez, Crisanto Díez-Quevedo, Cristina Miranda, Carmina R Fumaz, Maria J Ferrer, Bonaventura Clotet, TRIANT-TE Study Group   +10 more
doaj   +1 more source

Frankincense Upregulates the FMR1 Gene and Alleviates AlCl3-Induced Memory Impairment in Rats [PDF]

Journal of Genetic Resources, 2021
Alzheimer's disease (AD) is a multifactorial disorder that its progress and development are related to various genetic and environmental factors.
Mohammad Khalaj-Kondori, Mina Khajehdehi, Zeinab Shaghaghi Torkdari   +2 more
doaj   +1 more source

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background: Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer’s disease (AD). Methods: AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were ...
M.R. Farlow, P.M. Doraiswamy, X. Meng, K. Cooke, M. Somogyi   +4 more
doaj   +1 more source

The effect of single and repeated doses of rivastigmine on gastric myoelectric activity in experimental pigs.

PLoS ONE, 2023
BackgroundRivastigmine is a pseudo-irreversible cholinesterase inhibitor used for therapy of Alzheimer's disease and non-Alzheimer dementia syndromes. In humans, rivastigmine can cause significant gastrointestinal side effects that can limit its clinical
Chrysostomi Christina Tsianou, Jaroslav Kvetina, Vera Radochova, Darina Kohoutova, Stanislav Rejchrt, Martin Valis, Jana Zdarova Karasova, Ilja Tacheci, Veronika Knoblochova, Ondrej Soukup, Jan Bures   +10 more
doaj   +1 more source

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

BMC Geriatrics, 2005
Background Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer's disease (AD). Data supporting the safety and efficacy of second-generation cholinesterase inhibitors, such as rivastigmine, are ...
Lilly Mary L, Farlow Martin R
doaj   +1 more source

Atypical Presentation of Acetylcholinesterase Inhibitor-Induced Diarrhea in Older Adults with Cognitive Decline: An Aspect not to be Underestimated [PDF]

Annals of Geriatric Medicine and Research, 2023
The rivastigmine patch is the only existing transdermal delivery system used for the treatment of Alzheimer disease. Among the most common adverse events derived from its use are gastrointestinal events, particularly diarrhea.
Raffaele Pagliuca, Mario Virgilio Papa, Pagliuca Mena Ilaria, Virginia Federica Papa, Gina Varricchio   +4 more
doaj   +1 more source

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease

Current Research in Pharmacology and Drug Discovery, 2022
Alzheimer's Disease (AD) is characterized as a progressive neurodegenerative disease most commonly associated with memory deficits and cognitive decline.
Yasir Hasan Siddique, Falaq Naz, Rahul, Himanshi Varshney   +3 more
doaj   +1 more source

Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease

, 2008
Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer's disease (AD) indicate that the short and long term actions of ChEIs are dissimilar. fMRI studies of the ChEI rivastigmine have focused on its short term action.
Shanks, Michael F, Venneri, Annalena, McGeown, William J, Annalena Venneri   +3 more
core   +1 more source